VTGN – vistagen therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4/23
11:00 am
vtgn
Low
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Connect
4/22
08:30 am
vtgn
High
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
3/21
01:31 am
vtgn
Low
VistaGen Therapeutics (VTGN) was downgraded by Wall Street Zen from "
3/17
03:49 pm
vtgn
Low
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
3/16
04:00 pm
vtgn
Low
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen Therapeutics, Inc. Lawsuit – VTGN
2/12/2026
04:30 pm
VTGN
-10.9%
BEAT
11/13/2025
04:30 pm
VTGN
-0.3%
MISS
8/7/2025
04:30 pm
VTGN
8.0%
IN-LINE
4/13
05:28 pm
vtgn
Low
Form 8-K Vistagen Therapeutics, For: Apr 07
4/9
08:43 pm
vtgn
Low
Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Tressler Nick B.
4/9
08:42 pm
vtgn
Low
Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Singh Shawn
4/9
08:40 pm
vtgn
Low
Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Prince Joshua S.
4/9
08:38 pm
vtgn
Low
Form 4 Vistagen Therapeutics, For: Apr 07 Filed by: Cote Elissa S.
Show more
Top News Gainers
12/10 U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder 26.5%
3/25 VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million 24.6%
12/12 Form 8-K VistaGen Therapeutics, For: Dec 10 23.7%
7/23 VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray 11.1%
4/27 Form 4 VistaGen Therapeutics, For: Apr 23 Filed by: Underdown Brian J. 8.7%
11/8 Form 8-K VistaGen Therapeutics, For: Nov 07 8.0%
1/31 Form 8-K VistaGen Therapeutics, For: Jan 30 7.2%
8/1 Vistagen Therapeutics Inc (NASDAQ: VTGN) had its "neutral" rating re-affirmed by analysts at Chardan Capital. 6.3%
10/11 Vistagen Therapeutics Inc (NASDAQ: VTGN) was given a new $4.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 5.8%
12/12 Form D VistaGen Therapeutics, 5.4%
Top News Decliners
11/14 VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder -72.7%
2/11 VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects -24.4%
2/20 VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder -21.6%
10/1 Form S-8 POS VistaGen Therapeutics, -15.9%
1/30 VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients -14.5%
12/28 Vistagen Therapeutics Inc (NASDAQ: VTGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -12.1%
4/15 Form 424B3 VistaGen Therapeutics, -11.8%
2/13 Form 10-Q VistaGen Therapeutics, For: Dec 31 -10.9%
10/9 Form 8-K VistaGen Therapeutics, For: Oct 08 -10.5%
7/23 Form DEF 14A VistaGen Therapeutics, For: Jul 26 -10.4%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3